It's a prospective, single arm, open label phase II clinical trial, in which the safety and
efficacy of Chidamide plus R-CHOP regimen is accessed in de novo DLBCL patients, who have
received 2 courses of R-CHOP but only achieved PR or whose MRD tests for ctDNA revealed
positive results.
abbreviation: R-CHOP: the chemo-therapy regimen composed of Rituximab, cyclophosphoamide,
etoposide, vincristine and prednisone.
PR: partial remission; MRD:minimal residual disease;